Lead Paragraph
Nordhealth, a Helsinki-based healthcare software provider, presented its Q2 2026 Capital Markets Day results on August 18, 2026, highlighting progress towards becoming the most AI-native PMS in the vet & therapy markets while extending its timeline for profitability. The company crossed the €52 million signed annual recurring revenue milestone during the quarter.
Body
Nordhealth reported first-half 2026 recurring revenue of €25.2 million, up 13% year-over-year. However, adjusted EBITDA minus capital expenditures remained negative at €2.2 million for the half, as the company invested heavily in artificial intelligence product development and geographic expansion.
The company operates two distinct business verticals serving a combined 17,640 practices daily. The veterinary business, anchored by the Provet platform, serves 4,320 practices with 21,300 active veterinarians, while the therapy segment supports 13,320 practices with 27,000 therapists primarily in the Nordic region. Both units share a common technology foundation and AI development roadmap, though they target different end markets and exhibit distinct unit economics.
A central theme of the presentation was Nordhealth’s transformation from a traditional practice management system into what it terms a "system of action" powered by artificial intelligence. The company highlighted six AI agents now live in production, representing a significant acceleration in product development velocity.
AI Product Strategy
The six live agents include AI Scribe for automated clinical note-taking, AI Billing that converts consultations into billable items, AI Reporting for natural language data queries, patient history summarization, discharge note generation, and automated form filling. Management emphasized that these agents are already processing work at scale, with more than 600,000 journal notes created by AI in the therapy business alone.
Veterinary Business
The veterinary segment delivered 13.6% year-over-year ARR growth in the last twelve months ending June 2026, reaching €29.7 million. The business demonstrated exceptionally strong unit economics, as shown in the following performance summary:
The 2.2% gross churn rate and 26.7x LTV/CAC ratio reflect what management described as "the last system a clinic would switch off," emphasizing the mission-critical nature of practice management software. The 40% EBITDA minus CAPEX margin achieved in the mature Nordic markets provides a template for profitability as newer geographies scale.
Market Leadership
Despite this market leadership in Europe, Nordhealth’s current penetration remains low across its target markets. The company emphasized that significant growth opportunity exists within markets it already serves, requiring no new geographic expansion.
Subheading
Competitive Positioning
Nordhealth argues it holds unique advantages over both incumbent practice management systems and AI-focused startups. Unlike legacy providers, it has modern cloud architecture and an AI-native development team. Unlike pure-play AI companies, it controls the complete clinical record, workflow integrations, and compliance frameworks that agents require to act safely within healthcare settings.
Market-by-Market Analysis
The total addressable market opportunity is substantial, as illustrated in the following market-by-market analysis:
The United States represents the largest addressable market, with a total addressable market opportunity of €1.4 billion. The Nordic region, where Nordhealth already has a strong presence, is also a significant market, with a total addressable market opportunity of €1.1 billion.
Subheading**
AI Development Roadmap
Management emphasized that this infrastructure work—spanning data warehousing, modern cloud-native architecture, compliance frameworks, and scale—represents "unglamorous work nobody can skip" but provides a durable competitive moat.
Subheading**
Market Share
Nordhealth holds commanding positions in Norway (77% share), Finland (70%), and Sweden (56%), but remains in early-stage expansion in larger markets including the United Kingdom (14% share), Germany (12%), and the United States (1%). The company positioned these growth markets as the primary drivers of future veterinary revenue expansion.